ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Significant Decrease in Short Interest

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) saw a large decrease in short interest in November. As of November 30th, there was short interest totalling 1,840,000 shares, a decrease of 12.8% from the November 15th total of 2,110,000 shares. Based on an average daily volume of 292,900 shares, the short-interest ratio is presently 6.3 days.

Analyst Upgrades and Downgrades

ANIP has been the topic of a number of research reports. Truist Financial upped their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a research note on Tuesday, October 22nd. Piper Sandler assumed coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an "overweight" rating and a $68.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. StockNews.com lowered ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, September 7th. Finally, Leerink Partnrs upgraded ANI Pharmaceuticals to a "strong-buy" rating in a report on Wednesday. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, ANI Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $77.71.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock traded up $0.03 during mid-day trading on Friday, reaching $56.59. 229,635 shares of the company's stock were exchanged, compared to its average volume of 221,470. The business's fifty day simple moving average is $58.01 and its 200 day simple moving average is $60.29. The firm has a market capitalization of $1.19 billion, a PE ratio of -102.89 and a beta of 0.73. ANI Pharmaceuticals has a one year low of $51.79 and a one year high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to analysts' expectations of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm's quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.05 earnings per share. On average, sell-side analysts expect that ANI Pharmaceuticals will post 3.87 earnings per share for the current year.

Insider Activity at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 33,481 shares of the company's stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares of the company's stock, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at approximately $2,943,540. This trade represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,731 shares of company stock worth $2,015,861 in the last 90 days. Corporate insiders own 12.70% of the company's stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Global Alpha Capital Management Ltd. grew its position in shares of ANI Pharmaceuticals by 1.8% in the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock valued at $32,005,000 after purchasing an additional 9,500 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in shares of ANI Pharmaceuticals in the second quarter valued at $228,000. Thompson Siegel & Walmsley LLC grew its position in shares of ANI Pharmaceuticals by 17.6% in the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company's stock valued at $13,731,000 after purchasing an additional 34,416 shares in the last quarter. Thrivent Financial for Lutherans grew its position in shares of ANI Pharmaceuticals by 2.3% in the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock valued at $777,000 after purchasing an additional 299 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in ANI Pharmaceuticals by 15.4% during the second quarter. Renaissance Technologies LLC now owns 156,802 shares of the specialty pharmaceutical company's stock worth $9,985,000 after buying an additional 20,900 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.